This book aims to provides an overview of the advancements in histone modifiers and their targeted drugs in the field of cancer immunotherapy. It systematically examines the biological relationships between diverse histone modifications and tumor immunity, as well as the development of targeted inhibitors and degraders, drawing from clinical and literature research. This book will help readers understand the latest research advancements and guide them in the practice of cancer immunotherapy. The book is likely to be of interest to researchers in the field of new drug development and relevant graduate students.

Yi-Chao Zheng got his BS degree in pharmaceutical science from China Pharmaceutical University (China) in 2008, his MS degree in pharmacy from Katholieke Universiteit Leuven (Belgium) in 2010, and his PhD in medicinal chemistry from Zhengzhou University (China) in 2014. He is currently a full professor in the School of Pharmacal Sciences at Zhengzhou University. His current research interest resides in the identification of epigenetic targeted drug and their biological study. He is the author/coauthor of more than 88 publications in scientific journals, with an H-index of 32.